|
Written by Emma P. Hitt, PhD
|
|
Monday, 18 August 2008 |
|
Injectable, extended-release naltrexone (Vivitrol, Cephalon), used for the treatment of alcohol dependence, has been linked to adverse injection-site reactions, some requiring surgery, according to a US Food and Drug Administration (FDA) advisory notice to healthcare professionals released yesterday. |
|
Read more...
|